9. New ISCOMs Meet Unsettled Vaccine Demands

  1. Manmohan Singh M. Pharm., Ph.D.
  1. Bror Morein1,
  2. Kefei Hu1,
  3. Karin Lövgren2 and
  4. Erik D'Hondt3

Published Online: 2 NOV 2006

DOI: 10.1002/9780470134931.ch9

Vaccine Adjuvants and Delivery Systems

Vaccine Adjuvants and Delivery Systems

How to Cite

Morein, B., Hu, K., Lövgren, K. and D'Hondt, E. (2007) New ISCOMs Meet Unsettled Vaccine Demands, in Vaccine Adjuvants and Delivery Systems (ed M. Singh), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470134931.ch9

Editor Information

  1. Novartis Vaccines, Emeryville, California, USA

Author Information

  1. 1

    Department of Medical Sciences, Section of Virology, University Hospital, Uppsala University, and Iscovent AB, Uppsala, Sweden

  2. 2

    Isconova AB, Dag Hammarskjölds väg 54A, Uppsala, Sweden

  3. 3

    Rupelmondestraat 16, B-9150 Bazel, Belgium

Publication History

  1. Published Online: 2 NOV 2006
  2. Published Print: 15 JUN 2007

ISBN Information

Print ISBN: 9780471739074

Online ISBN: 9780470134931



  • new immunostimulating complexes (ISCOMs) and vaccine demands;
  • targeting devices on ISCOM and ISCOM-matrix;
  • novel ISCOM formulations


This chapter contains sections titled:

  • Introduction

  • Concept and Structure of the Immunostimulating Complex

  • ISCOM Technology

  • Examples Illustrating that ISCOMs Induce Immune Protection Against Different Pathogens in Different Species

  • Registered Vaccines Based on ISCOM Technology

  • Lessons Learned from ISCOM Vaccines in Animal Experiments

  • ISCOM Vaccine Candidates in Human Clinical Trials

  • Novel ISCOM Formulations

  • Properties of Special Interest

  • Conclusions

  • References